Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1707-1713

  Birjmohun, R S ^a   Kastelein, John J P ^a   Poldermans, D ^b   Stroes, E S G ^a   Hostalek, U ^c   Assmann, G ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MERCK KGAA   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Dyslipidaemia; HDL cholesterol; Niacin; Nicotinic acid; Tolerability, safety

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRITIS; ARTICLE; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GOUT; HALLUCINATION; HEART PALPITATION; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VASODILATATION;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FLUSHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES;

EID: 34547205154     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199682     Document Type: Article

References (24)

1. Bruckert E, Baccara-Dinet M, McCoy F, et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21: 1927-34
2. Kastelein JJP. The realities of dyslipidaemia: what do the studies tell us? Eur Heart J Suppl 2005;7:F27-33
3. International Atherosclerosis Society. Harmonized guidelines on prevention of atherosclerotic cardiovascular diseases. Available at: www.athero.org/download/fullreport.pdf [Last accessed February 2007]
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
5. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115: 114-26
6. Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. Available at www.idf.org [Last accessed February 2007]
7. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 Suppl 5:v1-52
8. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health/National Heart Lung and Blood Institute. Available at www.nhlbi.nih.gov/guidelines/cholesterol. [Last accessed February 2007]
9. Niaspan® Summary of Product Characteristics, Merck KGaA
10. McGovern M. Niaspan®: creating a new concept for raising HDL-cholesterol. Eur Heart J Suppl 2005;7:F41-7
11. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and nicotinic acid, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345: 1583-92
12. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
13. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142: 95-104
14. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-nicotinic acid on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-17
15. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of prolonged-release nicotinic acid on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
16. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and prolonged-release nicotinic acid on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
17. Vogt A, Kassner U, Hostalek U, et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006;22:417-25
18. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15
19. PROCAM risk calculator. Available at http://chdrisk.uni-muenster.de/ calculator.php [Last accessed February 2007]
20. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily nicotinic acid/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8
21. Reasner CA. Achieving the therapeutic benefits of Niaspan® in daily practice. Eur Heart J Suppl 2006;8:F68-73
22. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2006;16:132-143
23. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of a prolonged-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
24. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4